title: Von der Beratung über die Nutzenbewertung bis zur Erstattungsbetragsfindung von neuen Arzneimitteln: Eine Analyse des AMNOG auf Basis einer Methodentriangulation unter Verwendung biometrischer, akteurszentrierter und gesundheitsökonomischer Ansätze
Creators: name: Dintsios, Charalabos-Markos
Publisher: name: Bergische Universität Wuppertal
Year: 2022

description: Liste der Publikationen der kumulativen Dissertation: Liste der Publikationen der kumulativen Dissertation Dintsios, C.M., Schlenkrich, S. (2018). Industry’s Experiences with the Scientific Advice offered by the Federal Joint Committee within the Early Benefit Assessment of Pharmaceuticals in Germany. International Journal of Technology Assessment in Health Care 34: 196–204, DOI: 10.1017/S0266462317004536 Bender, H., Dintsios, C. M. (2018). Gesundheitsbezogene Lebensqualität im Rahmen der frühen Nutzenbewertung von Arzneimitteln nach § 35a SGB V: Ein Endpunkt mit vielen Herausforderungen für alle beteiligten Akteure. Gesundheitswesen 80: 132–143, DOI: 10.1055/s-0042-116433 Niehaus, I., Dintsios, C. M. (2018). Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs. Health Policy 122: 599–606, DOI: 10.1016/j.healthpol.2018.03.017 Molitor, M., Dintsios, C. M., (2021). Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA. Expert Review of Pharmacoeconomics &amp; Outcomes Research 21: 145–157, DOI: 10.1080/14737167.2020.1729131 Herpers, M., Dintsios, C. M. (2019). Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany. The European Journal of Health Economics 20: 45–57, DOI: 10.1007/s10198-018-0981-3 Dintsios, C. M., Worm, F., Ruof, S., Herpers, M. (2019). Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree. Health Economics Review 9:35 1–15, DOI: 10.1186/s13561-019-0254-6 Ruof, J., Staab, T., Dintsios, C.M., Schröter, J., Schwartz, F.W. (2016). Comparison of postauthorization measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified? Health Economics Review 6:46 1–11, DOI: 10.1186/s13561-016-0124-4 Staab, T.R., Walter, M., Mariotti Nesurini, S., Dintsios, C.M., Graf von der Schulenburg, J.M., Amelung, V.E., Ruof, J. (2018). “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Economics Review 8:23 1–11, DOI: 10.1186/s13561-018-0209-3 Gandjour, A., Schüßler, S., Hammerschmidt, T., Dintsios, C.M. (2020). Predictors of negotiated prices for new drugs in Germany. The European Journal of Health Economics 21:1049–1057, DOI: 10.1007/s10198-020-01201-z Worm, F., Dintsios, C. M. (2018). Determinants of Orphan Drug Prices in Germany. PharmacoEconomics 38: 397–411, DOI: 10.1007/s40273-019-00872-8 Dintsios, C. M., Beinhauer, I. (2020). The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.Health Economics Review 10:7 1–25,DOI: 10.1186/s13561-020-00263-2 Ludwig, S., Dintsios, C. M. (2016). Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years’ Experience. Value in Health 19: 1016– 1025, DOI: 10.1016/j.jval.2016.05.016 Dintsios, C. M. (2022). A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not? Expert Review of Pharmacoeconomics &amp; Outcomes Research 22: 283–297, DOI: 10.1080/14737167.2021.1930532